EdiGene, Inc., a global biotechnology company focused on translating gene-editing technologies into transformative therapies for patients with serious genetic diseases and cancer,
announced a non-exclusive, worldwide license agreement with Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, to access Arbor’s proprietary CRISPR gene editing technology for certain ex vivo engineered cell therapy programs in the field of oncology.
“Partnering with leading engineered cell therapy developers is a key component of Arbor’s strategy to broaden the potential of our CRISPR discovery engine beyond our wholly-owned in vivo genetic medicine approaches for the benefit of even more patients,” said Devyn Smith, Ph.D., Chief Executive Officer of Arbor. “We look forward to expanding the global impact of Arbor’s proprietary gene editing technologies through our partnership with EdiGene.”
The licensed technology is a part of Arbor’s proprietary CRISPR gene-editing portfolio, which is tailored to address the underlying pathology of genetic diseases.
“It has been great working with Arbor’s team in the past year to optimize ways of integrating Arbor’s proprietary CRISPR system into our ex vivo platforms,” said Dong Wei, Ph.D., CEO of EdiGene. “This partnership will expand EdiGene’s gene-editing toolkit and strengthen our capabilities to advance ongoing ex vivo gene-editing cell therapy programs for multiple serious diseases. We look forward to collaborating with Arbor to achieve our shared commitment to developing innovative therapies to address unmet medical needs.”
Under the agreement, EdiGene will pay Arbor certain upfront, milestone payments, commercial payments upon the achievement of certain development and sales milestones, and tiered royalties on net sales of royalty-bearing EdiGene products.